Celgene Sr. Research Associate - Proteomics in Cambridge, Massachusetts

Description

Celgene is a global biopharmaceutical company leading the way in medical innovation to help patients live longer, better lives. Our purpose as a company is to discover and develop therapies that will change the course of human health. We value our passion for patients, ​quest for innovation, spirit of independence and love of challenge. With a presence in more than 70 countries, and growing - we look for talented people to grow our business, advance our science and contribute to our unique culture.

Senior Research Associate in Proteomics

The Chemical and Structural Biology group at Celgene is seeking a motivated scientist to work on proteomic systems biology using quantitative mass spectrometry. We use state of the art technology to measure protein dynamics in response to drugs and disease. Specifically, by using proteomics mass spectrometry we aim to elucidate drug binding and mechanisms of action, disease molecular pathology and how the former can affect the latter. A successful candidate will have a diverse skill set in biochemical tools anchored in the specialist expertise of proteomics and mass spectrometry.

Responsibilities:

  • Apply a suite of biochemical approaches to culture, dose, enrich, digest, separate, and quantitate proteomics samples.

  • Develop novel sample preparation and mass spectrometry methods to establish robust, sensitive, efficient workflows.

  • Maintenance, QC and troubleshooting instruments including HPLCs and mass spectrometers.

  • Interpret and analyze data using a range of software tools and computational approaches.

  • Develop and apply supporting biochemical and molecular biology assays and tools.

  • Participate and contribute to scientific discussions, meetings and presentations.

  • Work on multiple projects, timelines and priorities in parallel

Technical Credentials, Skills & Experience:

  • BS plus 4+ years of relevant experience or MSc and 2+

  • Relevant experience includes –molecular biology, protein chemistry, biochemistry, analytical chemistry and chemical biology.

  • Proteomics specific experience is a major advantage: Q-Exactive, Lumos, TMT, SILAC, bRP-fractionation, affinity proteomics, shotgun acquisition, MaxQuant, Proteome Discoverer

  • Documentation, analysis, interpretation and presentation of experimental data in a clear and concise manner

Key Attributes:

  • Self-motivated to learn and contribute

  • Demonstrated examples of both independent productivity and team-based interpersonal skills

  • Enthusiasm for science, new technologies, laboratory work and drug discovery

  • An appreciation for details, efficiency, timelines, robustness and rigor

#LI-POST

Celgene is committed to equal opportunity in the terms and conditions of employment for all employees and job applicants without regard to race, color, religion, sex, sexual orientation, age, gender identity or gender expression, national origin, disability or veteran status. Celgene complies with all applicable national, state and local laws governing nondiscrimination in employment as well as employment eligibility verification requirements of the Immigration and Nationality Act. All applicants must have authorization to work for Celgene in the U.S.COMMITTED TO IMPROVING THE LIVES OF PATIENTS WORLDWIDE

At Celgene, we seek to deliver truly innovative and life-changing drugs for our patients. Our vision as a company is to build a major global biopharmaceutical corporation while focusing on the discovery, the development, and the commercialization of products for the treatment of cancer and other severe, immune, inflammatory conditions.

“At Celgene, we seek to deliver truly innovative and life-changing drugs for our patients.”

There are more than 300 clinical trials at major medical centers using compounds from Celgene. Investigational compounds are being studied for patients with incurable hematological and solid tumor cancers, including multiple myeloma, myelodysplastic syndromes, chronic lymphocytic leukemia (CLL), non-Hodgkin’s lymphoma (NHL), triple-negative breast cancer and pancreatic cancer. As committed as we are to clinical accomplishment, we are equally committed to patient support, which is a guiding principle at Celgene. We believe all who can benefit from our discoveries should have the opportunity to do so. Celgene puts patients first with industry-leading programs that provide information, support and access to our innovative therapies.